Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool. - PubMed - NCBI

Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool. - PubMed - NCBI

J Natl Cancer Inst. 2016 Aug 31;109(1). pii: djw181. doi: 10.1093/jnci/djw181. Print 2017 Jan.

Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool.

Imperiale TF1, Yu M2, Monahan PO2, Stump TE2, Tabbey R2, Glowinski E2, Ransohoff DF2.

Author information

Abstract

BACKGROUND:

There is no validated, discriminating, and easy-to-apply tool for estimating risk of colorectal neoplasia. We studied whether the National Cancer Institute's (NCI's) Colorectal Cancer (CRC) Risk Assessment Tool, which estimates future CRC risk, could estimate current risk for advanced colorectal neoplasia among average-risk persons.

METHODS:

This cross-sectional study involved individuals age 50 to 80 years undergoing first-time screening colonoscopy. We measured medical and family history, lifestyle information, and physical measures and calculated each person's future CRC risk using the NCI tool's logistic regression equation. We related quintiles of future CRC risk to the current risk of advanced neoplasia (sessile serrated polyp or tubular adenoma ≥ 1 cm, a polyp with villous histology or high-grade dysplasia, or CRC). All statistical tests were two-sided.

RESULTS:

For 4457 (98.5%) with complete data (mean age = 57.2 years, SD = 6.6 years, 51.7% women), advanced neoplasia prevalence was 8.26%. Based on quintiles of five-year estimated absolute CRC risk, current risks of advanced neoplasia were 2.1% (95% confidence interval [CI] = 1.3% to 3.3%), 4.8% (95% CI = 3.5% to 6.4%), 6.4% (95% CI = 4.9% to 8.2%), 10.0% (95% CI = 8.1% to 12.1%), and 17.6% (95% CI = 15.5% to 20.6%; P < .001). For quintiles of estimated 10-year CRC risk, corresponding current risks for advanced neoplasia were 2.2% (95% CI = 1.4% to 3.5%), 4.8% (95% CI = 3.5% to 6.4%), 6.5% (95% CI = 5.0% to 8.3%), 9.3% (95% CI = 7.5% to 11.4%), and 18.4% (95% CI = 15.9% to 21.1%; P < .001). Among persons with an estimated five-year CRC risk above the median, current risk for advanced neoplasia was 12.8%, compared with 3.7% among those below the median (relative risk = 3.4, 95 CI = 2.7 to 4.4).

CONCLUSIONS:

The NCI's Risk Assessment Tool, which estimates future CRC risk, may be used to estimate current risk for advanced neoplasia, making it potentially useful for tailoring and improving CRC screening efficiency among average-risk persons.

© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PMID:

 

27582444

 

DOI:

 

10.1093/jnci/djw181

[PubMed - in process]

Public Health Genomics Knowledge Base (v1.2)

COLORECTAL CANCER

Last Updated: Sep 08, 2016

• Adverse Clinical Outcome Associated With Mutations That Typify African American Colorectal Cancers.
  Wang Zhenghe et al. Journal of the National Cancer Institute 2016 Dec 108(12)
• Gene mutations that lead to more aggressive colorectal cancer in African American patients discovered
  Science Daily, September 2, 2016
• Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool.
  Imperiale Thomas F et al. Journal of the National Cancer Institute 2017 Jan 109(1)
• Germline PMS2 mutation screened by mismatch repair protein immunohistochemistry of colorectal cancer in Japan.
  Sugano Kokichi, et al. Cancer science 2016 9
• Have You or a Family Member Had Colorectal (Colon) Cancer? 
• Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors.
  Aprile Giuseppe, et al. Future oncology (London, England) 2016 8
• Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
  Paolicchi Elisa, et al. Oncology 2016 8
• Adverse Clinical Outcome Associated With Mutations That Typify African American Colorectal Cancers
  Z Wang, et al, JNCI, September 2016
• Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome.
  Tanakaya Kohji et al. Anticancer research 2016 Apr 36(4) 1985-9
• Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis.
  Takane Kiyoko, et al. Oncotarget 2016 8
• Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients.
  Khan Sajid A, et al. Journal of pediatric surgery 2016 8
• High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab.
  Hara Masayasu, et al. Surgery today 2016 8
• Colonoscopy uptake for high-risk individuals with a family history of colorectal neoplasia: A multicenter, randomized trial of tailored counseling versus standard information.
  Ingrand Isabelle et al. Medicine 2016 Aug 95(33) e4303
• Familial colorectal cancer: Patient assessment, surveillance and surgical management.
  Kennelly R P et al. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2016 Jul
• The impact of receiving predictive genetic information about Lynch syndrome on individual colonoscopy and smoking behaviours.
  Kim Joanne Soo-Min et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2016 Aug

• CDC Information (9)
• CDC-Authored Pub (13)

• Human (58)
• Pathogen (5)

• Human (4047)
• Pathogen (0)

• Human (234)
• Pathogen (0)

• Guidelines (16)
• Tier Table (19)
• Synthesis (58)

• Huamn (83)
• Pathogen (0)

Relevant Resources

• Cancer Genomics and Epidemiology Navigator (CGEN)
• Genetics and Genomics Competencies Center (G2C2)
• NIH Genetic Testing Registry
• NIH MedGen Database
• Online Mendelian Inheritance in Man (OMIM)
• PharmGKB